The two-year study will compare Amedica’s technology to polyetheretherketone (PEEK) interbody fusion devices. PEEK is a radiolucent, chemically-resistant thermoplastic that has been on the market for years and is used by surgeons for a variety of implant applications.
“Amedica is pleased to work with the University and its Medical Center to have the opportunity to further demonstrate the superiority of our silicon nitride spinal implants,” said Ben Shappley, CEO, president and director of Amedica, in a press release. “The results of the study will continue to solidify our technology’s position as the next generation in the market across all market segments, including spinal implants, reconstructive surgery and sports medicine applications. We continue to focus on cost effective patient care with enhanced outcomes.”
Learn more about Amedica.
Read more about Amedica:
– Trends and Developments Shaping the Future of Spine: Q&A With Ben Shappley of Amedica Corp.
– Amedica Receives Patent for Hip Implant
– Amedica and CEO Ben Shappley Featured in Utah News Coverage
